What is the common examiner trap about Science & Tech in UPSC exams?

Examiners may confuse aptamers with antibodies—aptamers are synthetic DNA/RNA, not proteins produced by the immune system. They may also swap 'CRISPR' as only a gene-editing tool, but the article highlights its use in biosensors for signal amplification. Another trap: stating that antibodies are the recognition element of choice in advanced biosensors (the article says aptamers have become the recognition element of choice).

What should UPSC aspirants remember about Science & Tech for Prelims?

1. Target this Data: Sepsis kills 11 million people every year. 2. Target this Data: First functional biosensor described in 1962 by Leland C. Clark, Jr. and Champ Lyons. 3. Target this Data: Aptamer-coated microneedle array reported in December 2025 for wearable monitoring.

Science & TechnologyHealth

Take AI Challenge ▸

News 0 of 31

Protein Biosensors: Aptamer-Nanotech-CRISPR Platforms Shrink Diagnosis Time for Sepsis, Cancer

Q: Who described the first functional biosensor in 1962?

Leland C. Clark, Jr. and Champ Lyons, The article states that in 1962, American biochemist Leland C. Clark, Jr. and microbiologist Champ Lyons described the first functional biosensor in the form of an electrode coated with an enzyme that reacted with glucose to produce a measurable electrical current.

Q: Consider the following statements: 1. Aptamers are synthetic DNA or RNA strands that bind selectively to target proteins. 2. Antibodies are cheaper and more stable than aptamers. 3. Researchers have developed aptamers for hundreds of disease-relevant proteins over the last two decades. Which of the statements given above is/are correct?

Both 1 and 3, Statement 1 is correct: aptamers are short, synthetic DNA or RNA strands that bind to target proteins with high selectivity. Statement 2 is incorrect: according to the article, aptamers are cheaper, more stable, and easier to manufacture than antibodies. Statement 3 is correct: over the last two decades, scientists have developed aptamers for hundreds of disease-relevant proteins.

Q: How many people die from sepsis every year according to the article?

11 million, The article explicitly states: 'Sepsis kills 11 million people every year.' The other options are distractors—5 million, 15 million, and 20 million are not mentioned in the article.

Q: What is the primary advantage of using nanomaterials like gold nanoparticles and graphene in protein biosensors?

They increase the surface area for protein binding and generate stronger signals, The article explains that the high surface area of nanomaterials gives more protein binding sites, while their electrical properties generate stronger signals, enabling detection of proteins even at low concentrations. Options A, C, and D are not supported by the article—nanomaterials enhance sensitivity but do not replace the transducer or recognition element.

Science & Tech Health & EducationHIGH

Target:UPSC GS-IIIMPSCTeachingPrelims HighMains Medium

15 Jul 2026

~2 min

Source: The Hindu

Key Data:11 million sepsis deaths per year1962 first biosensorDec 2025 microneedle arrayNov 2025 implantable sensor

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.Protein biosensors combine a biological recognition element (aptamer/antibody) with a transducer to detect disease-specific proteins in real time, enabling early diagnosis of sepsis, heart attack, and cancer.

2.Key technologies include aptamers (cheaper, stable synthetic DNA/RNA), nanomaterials (gold nanoparticles, graphene, MXenes) for sensitivity, and CRISPR-coupled sensors for amplified signals.

3.A sepsis sensor platform using gold-silver alloy nanostructures and machine learning can confirm infection and distinguish disease stages; wearable aptamer-coated microneedle patches for continuous monitoring are under development.

The Big Picture

Prelims · HighMains · Medium

Protein biosensors, using aptamers, nanotechnology, and CRISPR, can detect disease markers like sepsis, heart attack, and cancer in real time from a blood sample, drastically reducing diagnosis from 48 hours to minutes. This article explains the science, current landscape, and future potential of these rapid diagnostic tools for UPSC/SSC aspirants focusing on biotechnology in healthcare.

Exam Lens

Quick Exam Facts From News

Sepsis deaths per year11 million

First biosensor year1962

First biosensor inventorsLeland C. Clark, Jr. and Champ Lyons

Recognition element in advanced biosensorsAptamers (synthetic DNA/RNA)

Nanomaterials mentionedGold nanoparticles, carbon nanotubes, graphene, MXenes

CRISPR application in biosensorsCoupled with aptamers for amplified signal detection

Sepsis platform nanostructureGold-silver alloy

Wearable biosensor type (Dec 2025)Aptamer-coated microneedle array

1-Minute Revision

›Sepsis deaths per year: 11 million
›First biosensor year: 1962
›Target this Data: Sepsis kills 11 million people every year.
›Target this Data: First functional biosensor described in 1962 by Leland C. Clark, Jr. and Champ Lyons.
›Target this Data: Aptamer-coated microneedle array reported in December 2025 for wearable monitoring.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

🩸

Real-Time Sepsis Detection

A compact bedside sensor platform can detect multiple immune proteins linked to sepsis from a blood sample in real time, replacing 48-hour standard blood tests.

🧬

Aptamers Replace Antibodies

Researchers increasingly use aptamers (synthetic DNA/RNA) as recognition elements because they are cheaper, more stable, and easier to manufacture than antibodies.

📡

Closed-Loop Future Systems

Next-gen biosensors aim to use AI to interpret multi-protein signals and automatically trigger drug delivery, with implantable proof-of-concept demonstrated in Nov 2025.

Detailed Analysis & Strategic Depth

Context / Background

Proteins are crucial diagnostic targets as they change early in disease—troponin rises within hours of a heart attack, procalcitonin spikes during bacterial infections, and cancer-associated proteins appear before tumours are visible. Traditional diagnostics (e.g., blood cultures for sepsis) take 24–48 hours, delaying critical treatment. The first biosensor was conceived in 1962 by Clark and Lyons for glucose monitoring, using an enzyme-coated electrode. Modern biosensors pair a biological recognition element with a signal-converting transducer.

Core Analysis & Implications

The shift from antibodies to aptamers (synthetic DNA/RNA) is a key advancement—aptamers are cheaper, more stable, and can be produced entirely in the lab, avoiding biological manufacturing challenges. Nanotechnology (gold nanoparticles, graphene, MXenes) dramatically increases sensitivity by providing more binding sites and stronger electrical signals, enabling detection at low concentrations. The convergence with CRISPR allows target protein binding to trigger large, distinct signals—already demonstrated for malaria, SARS-CoV-2, and cancer biomarkers. The COVID-19 pandemic accelerated scaling of these rapid, portable diagnostics.

Future Outlook / Way Forward

Multi-marker detection platforms can now simultaneously detect several protein markers, offering the best chance for early diagnosis of high-mortality cancers like pancreatic cancer. Wearable monitoring (e.g., aptamer-coated microneedle patches for continuous inflammatory/cardiac monitoring) is under development. Closed-loop systems using AI to interpret outputs and trigger automated therapeutic responses (e.g., drug delivery) represent the next frontier—a proof-of-concept implantable sensor using genetically engineered bacteria was reported in Nov 2025. Key hurdles: degradation of recognition elements, individual baseline variability, scalability from lab prototypes, and regulatory approval requiring extensive clinical validation.

Key Facts at a Glance

Sepsis deaths per year11 million

First biosensor year1962

First biosensor inventorsLeland C. Clark, Jr. and Champ Lyons

Recognition element in advanced biosensorsAptamers (synthetic DNA/RNA)

Nanomaterials mentionedGold nanoparticles, carbon nanotubes, graphene, MXenes

CRISPR application in biosensorsCoupled with aptamers for amplified signal detection

Sepsis platform nanostructureGold-silver alloy

Wearable biosensor type (Dec 2025)Aptamer-coated microneedle array

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, State PSC

Who described the first functional biosensor in 1962?

Q2Statement-basedHardUPSC, SSC

Consider the following statements:

1. Aptamers are synthetic DNA or RNA strands that bind selectively to target proteins.

2. Antibodies are cheaper and more stable than aptamers.

3. Researchers have developed aptamers for hundreds of disease-relevant proteins over the last two decades.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, Banking, SSC

How many people die from sepsis every year according to the article?

Q4Application/ImpactMediumUPSC, SSC, Banking

What is the primary advantage of using nanomaterials like gold nanoparticles and graphene in protein biosensors?

All 25 MCQs ▸

Read original article from The Hindu

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Science & TechView Topic MCQs →Health & EducationView Topic MCQs →

Next Maharashtra Enacts Women Farmers Empowerment Act 2026: WFC De-links Land Ownership

Related Current Affairs

Science & Tech Current Affairs

Narayana Health Reports Success in Haplo-Cord Transplant for Thalassaemia & Dual-Target CAR-T for Brain Cancer

Doctors at Narayana Health, West Bengal, have successfully treated a 7-year-old thalassaemia patient using a Haplo-cord transplant and a 62-year-old brain cancer patient with dual-target CAR T-cell therapy. These breakthroughs highlight India's growing capability in advanced cell-based therapies and are landmark achievements in treating previously challenging conditions.

Science & Tech Current Affairs

RK-251: India's ROS-Activated Smart Cancer Drug Could Transform Chemotherapy

RK-251 is a novel 'smart' cancer drug developed by Indian researchers that activates only inside cancer cells using high reactive oxygen species (ROS) levels, potentially reducing chemotherapy side effects. This marks a significant advancement in targeted cancer therapy and is a key topic for UPSC Science & Technology.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Health & Education Current Affairs

WHO's IARC Classifies Hydrochlorothiazide, Voriconazole, Tacrolimus as Group 1 Carcinogens

Three widely used medicines for hypertension, fungal infections, and transplant rejection have been classified as Group 1 carcinogens by WHO's IARC. Patients are warned not to discontinue treatment without consulting doctors, as the classification identifies hazard, not real-world risk at prescribed doses.

Science & Tech Current Affairs

CSIR-IICT Develops IND-Ready Phytopharmaceutical from Gymnema sylvestre for Diabetic Foot Ulcers

CSIR-IICT has developed a phytopharmaceutical from the medicinal plant Gymnema sylvestre for diabetic foot ulcers, a major complication of diabetes. The technology has been transferred to Mumbai-based Viridis Biopharma for clinical development and regulatory approvals, including CDSCO and USFDA. This marks a significant step in India's evidence-based botanical drug discovery and academia-industry collaboration.

Science & Tech Current Affairs

SCTIMST Unveils Chitra Core Stent: 30-40% Less Metal, Reduces Restenosis & Thrombosis

SCTIMST has launched 'Chitra Core', a fully indigenous coronary stent with a patented design that uses 30-40% less metal than conventional stents, aiming to reduce complications like restenosis and thrombosis. A second stent, 'Chitra TiN' with a titanium nitride coating, is ready for global pre-clinical trials.

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Science & Tech Current Affairs

IISc Bengaluru Discovers Cow Enzyme CRhAB Effective Against Drug-Resistant Biofilm Bacteria Klebsiella & Acinetobacter

IISc Bengaluru has discovered a new cow enzyme (CRhAB) that breaks down biofilms of two major drug-resistant bacteria (Klebsiella pneumoniae & Acinetobacter baumannii) found in hospitals. This breakthrough, published in Nature, offers a potential new treatment for chronic wound infections and diabetic foot ulcers.

Start Today's Quiz(25 Qs)

Take Today's Quiz

25 Qs • 5-7 Mins

Protein Biosensors: Aptamer-Nanotech-CRISPR Platforms Shrink Diagnosis Time for Sepsis, Cancer

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Real-Time Sepsis Detection

Aptamers Replace Antibodies

Closed-Loop Future Systems

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance